136 related articles for article (PubMed ID: 37634608)
1. Hyperspectral imaging to predict the effect of cyclophosphamide in primary membranous nephropathy.
Liu W; Hou X; Li Y; Wang Z
Photodiagnosis Photodyn Ther; 2023 Dec; 44():103751. PubMed ID: 37634608
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.
Lin W; Li HY; Lin S; Zhou T
Drug Des Devel Ther; 2019; 13():2179-2186. PubMed ID: 31308629
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
[No Abstract] [Full Text] [Related]
6. Substitution of Oral for Intravenous Cyclophosphamide in Membranous Nephropathy.
Luzardo L; Ottati G; Cabrera J; Trujillo H; Garau M; González Bedat C; Coitiño R; Aunchayna MH; Santiago J; Baldovinos G; Silvariño R; Ferreiro A; González-Martínez F; Gadola L; Noboa O; Caorsi H
Kidney360; 2020 Sep; 1(9):943-949. PubMed ID: 35369556
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis.
Zhu LB; Liu LL; Yao L; Wang LN
Drugs; 2017 Feb; 77(2):187-199. PubMed ID: 28084563
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
[TBL] [Abstract][Full Text] [Related]
9. [The clinical efficacy and safety of modified Ponticelli regimen for treatment of idiopathic membranous nephropathy].
Xia W; Pei H; Li S; Fu S; Tian L
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):181-5. PubMed ID: 26926368
[TBL] [Abstract][Full Text] [Related]
10. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy.
Passerini P; Ponticelli C
Semin Nephrol; 2003 Jul; 23(4):355-61. PubMed ID: 12923723
[TBL] [Abstract][Full Text] [Related]
12. [A novel approach to rapid induction of remission in primary membranous nephropathy].
Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
Zou H; Jiang F; Xu G
Ren Fail; 2019 Nov; 41(1):673-681. PubMed ID: 31354007
[No Abstract] [Full Text] [Related]
14. Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.
van de Logt AE; Beerenhout CH; Brink HS; van de Kerkhof JJ; Wetzels JF; Hofstra JM
PLoS One; 2015; 10(11):e0142033. PubMed ID: 26562836
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Idiopathic Membranous Nephropathy: A Retrospective Study.
Rozenberg I; Kotliroff A; Zahavi T; Benchetrit S
Isr Med Assoc J; 2018 Mar; 20(3):186-189. PubMed ID: 29527859
[TBL] [Abstract][Full Text] [Related]
18. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis.
Liu D; Yang Y; Kuang F; Qing S; Hu B; Yu X
Int Immunopharmacol; 2019 May; 70():354-361. PubMed ID: 30852290
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive Treatments for Idiopathic Membranous Nephropathy: A Pilot Study According to Histopathological Stages.
Yan Z; Hu L; Xu G
Am J Med Sci; 2022 May; 363(5):444-451. PubMed ID: 34606753
[TBL] [Abstract][Full Text] [Related]
20. Hyperspectral imaging-based cutaneous wound classification using neighbourhood extraction 3D convolutional neural network.
Cihan M; Ceylan M
Biomed Tech (Berl); 2023 Aug; 68(4):427-435. PubMed ID: 36862718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
